Five months after launching, Acrivon Therapeutics secured $100 million in an oversubscribed Series B financing round to support the clinical development of a cancer asset licensed from Eli Lilly and advance the company’s precision proteomics platform.
Autolus Therapeutics is receiving as much as $250 million in funding after signing a collaboration deal with Blackstone Life Sciences to support the company’s cancer treatment research.
Novartis forged a collaboration with U.K.-startup Dunad Therapeutics to develop next-generation targeted protein-degradation therapies in a deal valued at up to $1.3 billion.
Teva Pharmaceutical Industries Ltd. inked a deal to license and develop two of MODAG GmbH’s compounds in neurodegenerative disease.
Novartis agreed to expand the company’s fill-and-finish support for the Pfizer/BioNTech Covid-19 vaccine by using manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022, the Swiss drugmaker said on Oct. 21.
Fresh off a presentation of positive data showing that the KRASG12C inhibitor adagrasib benefited colorectal and lung cancer patients, Mirati Therapeutics forged an agreement to combine the drug with Sanofi’s company’s SHP2 inhibitor SAR442720 in lung cancer.
Moderna is seeking to invalidate two patents belonging to Arbutus Biopharma that deal with drug-delivery technology.
A safety concern forced Takeda Pharmaceutical to suspend the dosing of patients in two Phase II studies of an experimental treatment for narcolepsy. The clinical trial halt came one day after the company forged a gene therapy agreement with Selecta Biosciences valued at $1.1 billion.
Boston Scientific entered into a deal to acquire Baylis Medical, a medical devices maker with headquarters in Canada, for an upfront payment of $1.75 billion in a bid to expand the Mass.-based company’s electrophysiology and structural heart product portfolio.
Cambridge, Mass.-based Voyager Therapeutics entered a deal allowing Pfizer to exercise options to license novel capsids for gene therapies.